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Background: The ZNF217 gene, encoding a C2H2 zinc finger protein, is located at 20q13 and found amplified and
overexpressed in greater than 20% of breast tumors. Current studies indicate ZNF217 drives tumorigenesis, yet the
regulatory mechanisms of ZNF217 are largely unknown. Because ZNF217 associates with chromatin modifying
enzymes, we postulate that ZNF217 functions to regulate specific gene signaling networks. Here, we present a
large-scale functional genomic analysis of ZNF217, which provides insights into the regulatory role of ZNF217 in
MCF7 breast cancer cells.
Results: ChIP-seq analysis reveals that the majority of ZNF217 binding sites are located at distal regulatory regions
associated with the chromatin marks H3K27ac and H3K4me1. Analysis of ChIP-seq transcription factor binding sites
shows clustering of ZNF217 with FOXA1, GATA3 and ERalpha binding sites, supported by the enrichment of
corresponding motifs for the ERalpha-associated cis-regulatory sequences. ERalpha expression highly correlates with
ZNF217 in lysates from breast tumors (n = 15), and ERalpha co-precipitates ZNF217 and its binding partner CtBP2
from nuclear extracts. Transcriptome profiling following ZNF217 depletion identifies differentially expressed genes
co-bound by ZNF217 and ERalpha; gene ontology suggests a role for ZNF217-ERalpha in expression programs
associated with ER+ breast cancer studies found in the Molecular Signature Database. Data-mining of expression
data from breast cancer patients correlates ZNF217 with reduced overall survival.
Conclusions: Our genome-wide ZNF217 data suggests a functional role for ZNF217 at ERalpha target genes. Future
studies will investigate whether ZNF217 expression contributes to aberrant ERalpha regulatory events in ER+ breast
cancer and hormone resistance.
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Recurrent and common genomic amplifications have led
to the discovery of important oncogenes and cancer
therapeutic targets. The 20q13 amplification including
the ZNF217 gene coding for a transcription factor is
found in ~ 20-30% of breast cancers and is associated
with aggressive tumor behavior, shorter disease-free
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unless otherwise stated.recent report shows that ZNF217 overexpression accel-
erates aberrant cell differentiation through signaling
events leading to increased self-renewal capacity, a mes-
enchymal phenotype, motility, chemoresistance and me-
tastasis in mammary mouse models [3]. Earlier work
using ChIP-chip tiling arrays for the 5 kb DNA region
surrounding the transcriptional start site (TSS) identified
ZNF217 regulatory gene targets in the embryonal carcin-
oma cell line, Ntera2, and the breast cancer cell line
MCF7 [4]. This work supported a developmental role
for ZNF217 as a regulatory factor at differentiation-
specific genes. Findings from this work led to the dis-
covery that ZNF217 directly activates ERBB3 andLtd. This is an Open Access article distributed under the terms of the Creative
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pathways [3,5,6]. Despite increasing knowledge of
ZNF217-induced phenotypes and regulation of path-
ways promoting tumorigenesis, there is a lack of under-
standing of the downstream ZNF217-induced effectors
driving these cell pathways.
ZNF217 encodes a transcription factor with eight
C2H2 zinc finger motifs and a proline-rich transactiva-
tion domain at the C-terminus [7]. ZNF217 has been re-
ported to physically interact with CtBP1/2 [7], an adaptor
protein found in multiple regulatory complexes at both
activated and repressed gene targets [5,7,8]. ChIP-chip
studies indicate CtBP and ZNF217 are co-bound at the
majority of ZNF217 DNA binding sites [4]. ZNF217 bio-
chemically purifies with histone deacetylases HDAC1/2
[9,10], histone demethylases LSD1 [10,11] and Jarid1b/
Plu-1 [11], and histone methyltranferases G9a and EZH2
[11], suggesting a range of regulatory functions in histone
modifying complexes. Based on our current knowledge of
ZNF217 and its association with DNA regulatory proteins,
it has been hypothesized that ZNF217 functions as an or-
ganizer of histone chromatin modifiers [11]. The cooper-
ating transcriptional mechanisms used by ZNF217, and its
association with specific regulatory elements remains
unexplored.
An important step in understanding the molecular role
of ZNF217 in breast cancer is to gain a more complete
understanding of the mechanisms of genome-wide gene
regulation by ZNF217 in breast cancer cells, including
the involvement of cooperating transcriptional partners.
In the current study we employed an integrative genom-
ics approach to uncover the mechanisms of ZNF217
target gene regulation in breast cancer cells. Using a
combination of RNA- and ChIP-seq techniques in MCF7
breast cancer cells, we focused on identifying genes that
were regulated by ZNF217 DNA binding. Our findings
suggest a functional association for ZNF217 with es-
trogen receptor alpha (ERα) at co-bound ERα gene
targets. This work supports further exploration into
the connection between ZNF217 expression levels in
breast tumors with clinical outcome and, importantly,
whether ZNF217 plays a transcriptional role in aber-
rant ERα signaling, contributing to breast cancer and
therapy resistance.
Results
ZNF217 genome-wide binding patterns
To elucidate the regulatory function of ZNF217 in breast
cancer, we performed genome-wide chromatin mapping
of ZNF217 by ChIP-seq using the ER+ HER2- MCF7 cell
line. Accordingly, we sequenced two independent ChIP-
seq replicates and determined a set of enriched ZNF217
binding sites, using the Sole-Search peak calling tool
[12], by taking the shared ZNF217 binding sites (FalseDiscovery Rate (FDR) < 0.0001) from both replicates (18,
965 binding sites; Additional file 1). These datasets agree
with the ENCODE guidelines for transcription ChIP-seq
overlap rules [13]. To determine the Refseq genes near-
est to each ZNF217 binding site, we used the Sole-
Search location analysis tool. This analysis identified
ZNF217 ChIP-seq targets at a total of 6,965 target genes
with multiple binding events occurring at 3,619 genes
(see Additional file 2). Our earlier work from MCF7
ChIP-chip promoter arrays identified ZNF217 binding
at the proximal promoter regions of 5,061 genes [4];
45% of these genes are present in the current ZNF217
ChIP-seq dataset. Analysis of distances between ZNF217-
associated regions and the nearest annotated TSSs
revealed that ZNF217 binds predominantly distal to
promoter regions; less than 10% of the sites are located
within 1 kb of annotated TSSs. In contrast, 15%, 52%,
and 26% of the sites are located within 1–10 kb, 10–
100 kb, and > 100 kb from a TSS, respectively (Figure 1A).
Interestingly, location analysis shows 6,348 binding sites
(33%) are located within genes (introns and exons), with
the majority (92%) within introns. A panel of ZNF217-
bound sites located at distal regions, including intronic
sites, was confirmed by ChIP qPCR (see Additional file 3).
ZNF217 binding at the proximal region of TFF1 and the
previously identified ZNF217 regulatory target, ERBB3 [5],
are also shown.
To further explore ZNF217 binding with respect to
specific regulatory elements (such as enhancers or si-
lencers), we analyzed the ChIP-seq read density relative
to the total number of ZNF217 binding sites in MCF7
using ChIP-seq datasets for a number of activating his-
tone marks including mono- and trimethylation of his-
tone H3 Lys4, acetyl histone H3 Lys27 (H3K4me1,
H3K4me3, H3K27ac, respectively), as well as the repres-
sive histone marks trimethylation of histone H3 Lys9
and trimethylation of histone H3 at Lys27 (H3K9me3
and H3K27me3, respectively). The heatmap in Figure 1B
shows a strong enrichment for H3K27ac and H3K4me1
relative to the center of the majority of ZNF217 sites
(cluster II). A small proportion of sites are also enriched
for H3K4me3 and H3K4me1 (cluster I). Location ana-
lysis on these ZNF217 binding sites indicate that the
cluster II binding sites are largely distal regions, whereas
the H3K4me3 enriched cluster I sites are largely pro-
moter proximal (see Additional file 4). These results
show that the majority of ZNF217 binding sites are
marked by active chromatin marks and that the predom-
inant class of binding events is located at distal regula-
tory elements associated with H3K4me1 and H3K27ac.
Recent reports demonstrated that active enhancer ele-
ments are marked by the histone acetyltransferase p300
and by enrichment of H3K4me1 at flanking nucleosomes
[14,15]. Indeed, using p300 ChIP-seq data we observe
Figure 1 Genome-wide analysis of ZNF217chromatin occupancy. (A) Distribution of ZNF217 binding sites relative to the nearest annotated
TSS. (B) Heatmaps depict H3K4me3, H3K27ac, H3K27me3, and H3K9me3 ChIP-Seq signals at regions spanning ZNF217 binding sites (±2 kb) in
MCF7 cells organized according to their chromatin status: cluster I and cluster II. Active K4me3-only (cluster I) sites are predominately promoters,
while K4me1 and K27ac sites (cluster II) are primarily enriched for distal regions. (C) Average p300 (black), H3K4me1 (red), and H3K27me3 (orange)
ChIP-seq enrichment profiles around central position of ZNF217 binding sites.
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ZNF217-bound regions, whereas H3K27me3 showed no
substantial enrichment (Figure 1C).
To glean insight into the function of ZNF217 binding,
we performed functional annotation of the top 5,000
ZNF217-bound regions with GREAT, a software tool de-
signed to assign biological function to noncoding gen-
omic regions [16]. This analysis showed an association
with ontological categories including mesoderm devel-
opment, mammary gland development and gastrulation.
The Pathway Commons category terms aligned with
ERα signaling and FOXA1 transcription networks.
ZNF217 binding sites associated with multiple genes in
TGFβ, WNT, and ER signaling pathways (gene associa-
tions are shown in Additional file 5).
ZNF217 binding sites are occupied by multiple
transcription factors
Another property of enhancer regions is their relative
abundance of binding sites for multiple transcription
factors [15,17]. To gain insight into the function ofZNF217 at distal regulatory regions in relation to other
transcriptional partners, we identified the predominant
motifs for known transcription factors near ZNF217
binding sites. We retrieved the 200 bp DNA sequence
for the ZNF217-bound regions and identified the most
significant motif logos using HOMER [17] (Figure 2A).
Our search identified enriched cis-regulatory sequences
for FOXA1 in 31%, GATA3 in 34%, and EREs at 20% of
the ZNF217 binding sites (Figure 2A) of which the dens-
ity of each motif is enriched ± 200 bp relative to the cen-
ter of the ZNF217 binding peak (Figure 2B). Next, we
searched for de novo motifs over-represented within
ZNF217-bound regions. We did not find enrichment of
the ZNF217 consensus sequences reported in our earlier
work [4], or the work of others [8]. We did however
identify a unique, non-repetitive sequence at ZNF217
sites: 5’-TGA(G/C)TCA(T/C)-3’ (or its reverse comple-
ment 5’-(A/G)TGA(C/G)TCA-3’). This de novo ZNF217
consensus site indicates enrichment of a sequence simi-
lar to the AP-1 motif (see Additional file 6). AP-1 motifs
are very often found near binding sites for many types of
Figure 2 ZNF217 binding sites cluster with transcription factor binding sites in MCF7 cells. (A) Top TF motifs enriched in ZNF217 binding
sites. (B) Distribution of identified motifs relative to the center of ZNF217 binding sites. Shown below are the motif logos for each TF. (C) ZNF217
shows co-binding with GATA3, FOXA1, TCF7L2, NR2F2 and ERα. Colors in the heat map reflect the colocalization frequency of each transcription
factor (the descending frequency of localization ranges from red to yellow to white).
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some as a “general” enhancer binding factor [18]. AP-1
is a transcription factor that interacts with ERα and
plays a role in the recruitment of ERα upon ligand bind-
ing to specific regulatory elements within the genome[18-21]. To further investigate the transcriptional part-
ners of ZNF217, we performed unsupervised clustering
analysis of all ENCODE ChIP-seq transcription factor
binding sites found in MCF7 cells. We found a group of
five transcription factors with binding sites that cluster
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ERα, GATA3, and FOXA1 (Figure 2C). This occupancy
and motif analysis highlights a significant interaction be-
tween ZNF217 and alternative breast cancer transcrip-
tion regulators.
Several proteins serve as pioneer factors contributing
to ERα action in breast cancer, including FOXA1 and
GATA3 (reviewed in [22]). We therefore assessed the
four-way overlap between these factors. Binding site
overlap analysis indicate a large fraction of the total
ZNF217 binding sites are shared by ERα, GATA3, and
FOXA1 in asynchronous MCF7 cells (Figure 3A and C).
In addition, this analysis reveals distinct combinations of
binding sites shared between these factors. We found
that while 41% of ZNF217 sites overlap with ERα (see
Additional file 7), there are other unique associations of
ZNF217 with GATA3 and FOXA1 independent of ERα
in MCF7 cells (Figure 3A). The individual sets of genes
bound by ZNF217 and each factor or groups of factors
are listed in Additional file 8. Heatmap clustering of the
read density from independent ERα, FOXA1, and
GATA3 ChIP-seq experiments supports the associationFigure 3 ZNF217 binding correlates with ERα, GATA3 and FOXA1. (A)
cells. Listed below the factor is the total number of binding sites for that d
density spanning ZNF217 binding sites (±2 kb) in MCF7 cells. (C) IGB snapsof these transcriptional regulators, where an enriched
signal is prevalent surrounding the center of ZNF217
binding sites (Figure 3B). One example of overlap between
ZNF217 with ERα, FOXA1, and GATA3 co-bound regions
is shown at the TFF1 gene, a well-known ER gene target
[23] (Figure 3C).
Depletion of ZNF217 identifies a gene expression
signature associated with ERα gene targets
To gain further insight into the regulation of gene ex-
pression by ZNF217, we employed an RNA-seq ap-
proach following ZNF217 silencing to characterize the
direct and indirect targets of ZNF217 in MCF7 breast
cancer cells. We treated cells with ZNF217-targeting
short interfering RNA (siRNA) leading to ZNF217 mRNA
and protein depletion (see Additional file 9) and per-
formed gene expression profiling by RNA-seq. We identi-
fied 3,402 differentially expressed genes; 1,615 genes were
up-regulated and 1,787 were down-regulated genes in the
ZNF217 knockdown sample, as compared to the control
(siScramble) siRNA-treated sample (at 1.25 -fold change
cutoff and criteria representing statistical significance,A four-way comparison of binding sites shared with ZNF217 in MCF7
ataset. (B) Heatmap depicting ERα, GATA3 and FOXA1 ChIP-seq signal
hot of ZNF217, ERα, GATA3 and FOXA1 occupancy at the TFF1 gene.
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Additional file 10; Figure 4A). RNA-seq results were con-
firmed by RT-qPCR on a small panel of genes (Figure 4B).
To determine if the genes that changed with ZNF217 si-
lencing are also bound by ZNF217, we integrated the
ChIP-seq and RNA-seq datasets and compared the ex-
pression of genes with a ZNF217 binding site. Among the
3,402 differentially expressed genes, following ZNF217 si-
lencing, 1,230 (36%) of the ZNF217-bound genes change
with ZNF217 knockdown. In addition, we find that 62%
and 38% of the 1,230 differentially expressed genes with a
ZNF217 binding site show increased and decreased ex-
pression, respectively (Figure 4C). We also found that
among a total 4,442 genes co-bound by ZNF217 and
ERα, 854 genes change in expression with ZNF217
silencing of which 60% (512 genes) show increased
expression levels (Figure 4C). Independent RT-qPCR
experiments validate the increased levels of the
known estrogen responsive ERα-target genes LRIG1
[24] and SLC22A5 [25] and the decreased levels of
AXIN1 and IGFBP4 following ZNF217 depletion
(Figure 4B and Additional file 11).Figure 4 Analysis of gene expression changes upon ZNF217 knockdo
experiments. Each point corresponds to one NCBI Reference Sequence (Re
mapped reads (FPKM) values for control and ZNF217 knockdown samples
< 0.05 with a 1.25-fold change cuttoff) are depicted (red upregulated and b
sents no change in gene expression between the two samples. (B) The trip
siZNF217- treated MCF7 cells were analyzed by quantitative RT-PCR. ABI ex
are indicated. Each sample was assayed in triplicate and the cT values were
using BioRad CFX software. Columns: transcript levels, error bars: standard erro
lated or upregulated by depletion of ZNF217 and bound by ZNF217, ERα, orThe ZNF217 gene signature identifies gene set
enrichments from ER+ breast cancer studies
To understand the genes regulated by ZNF217 and the
pathways associated with ERα function, we performed
gene ontology analysis on the lists of differentially regu-
lated genes following ZNF217 silencing with the GREAT
classification gene ontology tool [16]. Interestingly,
both the list of 1,230 ZNF217-bound differentially
regulated genes and the list of 854 ZNF217-ERα
co-bound differentially regulated genes show strong
associations with genes associated with multiple
cancer studies present in the Molecular Signatures
Database (MSigDB) [26]. Genes in the ZNF217-ERα
co-bound list correlate with genes identified from
key cancer studies including: (a) Genes found up-
regulated or down-regulated in breast cancer tumors
(formed by MCF-7 xenografts) resistant to tamoxifen
(Massarweh [27]), (b) Genes up-regulated in luminal-
like breast cancer cell lines compared to basal or
mesenchymal-like ones (Charafe [28]), (c) Genes associ-
ated with acquired endocrine therapy resistance in breast
tumors expressing ESR1 but not ERBB2 (Creightonwn in MCF7 cells. (A) A scatterplot of expression data from RNA-seq
fSeq) transcript with fragments per kilobase of exon model per million
shown on an exponential scale. Significantly affected transcripts (FDR
lue downregulated upon ZNF217 knockdown). The dashed line repre-
licate biological (sequenced) RNA samples from siScrambled- or
pression assay Taqman probes to measure transcript levels of six genes
normalized to GAPDH. Average relative transcript level was graphed
r of the mean. (C) Summary of differentially expressed genes, downregu-
both ZNF217 and ERα.
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(stem) cells corresponding to side population (SP) MCF7
cells positive for MUC1 (Engelmann [30]), (e) Genes up-
regulated in MCF-7 cells under hypoxia and (Elvidge
[31]), (f) Genes that change according to the ESR1 status:
ER positive vs ER negative tumor (Doane [32]), and (g)
Genes up-regulated in MCF7 cells (breast cancer) after
stimulation with NRG1 (Nagashima [33]). The enrich-
ments of the ZNF217-ERα co-bound MSigDB categories
are shown in Figure 5. A comparison of the complete list
of cancer studies associated with ZNF217-bound and
ZNF217-ERα co-bound genes are in Additional file 12.
We were particularly interested in the combined up-
and down-regulated ZNF217 differentially expressed
genes (169) associated with the Massarweh expression
study [27]. Gene ontology for the 169 genes showed
functional classification associating with developmental
pathways; many of these genes are known estrogen-
responsive ERα target genes (data not shown). The gene
expression changes found in tamoxifen-resistant tumors
(derived from MCF7 xenografts) included several genes
either up or down-regulated by ZNF217 and co-bound
by ZNF217- ERα including CAV2, ELF5, ID2, TGFB2,
LRIG1, FOXO3, CXCL12, and CD44.
ZNF217 and ERα precipitate in MCF7 nuclear extracts
Our genome-wide binding analysis indicates ZNF217 is
associated with ERα and other regulatory factors at “ac-
tive” DNA regulatory elements. It is well-known that nu-
clear receptors do not function in isolation but requireFigure 5 Analysis of gene expression changes upon ZNF217 knockdow
GREAT gene ontology on the 854 ZNF217-ERα co-bound gene list identifies oco-factors to assist with DNA interaction; intensive work
in the field of estrogen receptor biology has sought to
identify critical factors that affect ERα-mediated tran-
scription [34]. To identify potential unknown regulators
of ERα, Jason Carroll’s group performed a novel ap-
proach termed RIME (Rapid Immunoprecipitation with
ERα followed by Mass spectrometry of Endogenous pro-
teins). This work identified an association between ERα
and 108 proteins, including the association of ZNF217
and the binding partners, CtBP1/2, in three out of three
replicate experiments [35]. To confirm this finding, we
tested whether or not ZNF217 associates with ERα in
MCF7 nuclear extracts by co-immunoprecipitation as-
says. Immunoblotting of lysates showed ERα precipitated
both ZNF217 and the ZNF217-binding partner CtBP2
(see Additional file 13).
ZNF217 is enriched in ER+ breast cancer
If ZNF217 interacts with ERα and potentially contributes
to the chromatin landscape associated with ERα binding,
then we reasoned that ZNF217 expression might be
higher in estrogen receptor positive (ER+) tumors. Using
microarray expression studies of breast tumors across
multiple patient cohorts, we found that ZNF217 expres-
sion levels are higher in ER+ tumors than in ER- tumors
(data-mining from the Chin 2006 [36] and the Hess
2006 [37] studies are shown in Figure 6A and B). We
next compared ZNF217 expression levels across patient
subtypes: Luminal A, Luminal B, ERBB2+, basal, and nor-
mal. Patient data from the Chin and Hess studies indicaten in MCF7 reveals deregulation of breast cancer gene signatures.
verlap with several MSigDB Cancer Studies (p < 10−8, exact binomial test).
Figure 6 High ZNF217 expression is enriched in ER + breast cancer. (A) Estrogen receptor status from Chin et al. 2006 study [36]. ZNF217
expression levels in primary tumors that were ER positive (n = 75) or ER negative (n = 43) compared by Mann–Whitney t-test (p = 0.009). (B)
Estrogen receptor status from Hess et al. 2006 study [37]. ZNF217 expression levels in primary tumors that were ER-positive (n = 82) or negative
(n = 51) and compared by Mann–Whitney t-test (p≤ 0.001). (C) ZNF217 expression levels in patients separated by gene expression molecular sub-
types (p = 0.0003; ANOVA,Kruskal-Wallis) from Chin et al. 2006 [36] study. (D) ZNF217 expression levels in patients separated by gene expression
molecular subtypes (p = 0.0002; ANOVA,Kruskal-Wallis) from Hess et al. 2006 [37] study. For both analyses, individual cohort combinations were
compared by Dunn’s multiple comparison test, and those marked with * had p < 0.05. Each line marks the mean for the subtype. (E) Immunoblotting
of 15 breast tumor lysates with antibodies to ZNF217, ER, or actin as a loading control. ZNF217 and ER protein densitometry was quantitated (r2 = 0.93).
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lowest in basal subtype tumors (Figure 6C and D).
We previously found that high ZNF217 expression is a
prognostic indicator in general as well as in ER+HER2+LN−
patients with breast cancer correlating with shorter overall,
disease-specific, and relapse-free survival [3]. We next
wanted to determine if ZNF217 overexpression had prog-
nostic value exclusive of estrogen receptor status. We
found that high ZNF217 expression consistently predicted
poor prognosis across multiple tumor subtypes: Luminal,
ER−, HER2+/ERBB2+, and basal cohorts ([3] and Additional
file 14). Together, our data show that ZNF217 is prognostic
of reduced survival in ER+, ER−, HER2+/ERBB2+, Luminal,
and basal subtype patients by univariate analysis. Moreover,
ZNF217 was a better predictor of survival than ERα status
but not tumor size by multivariate analysis [3].
We also looked for a correlation between ZNF217 and
ERα protein expression in breast tumor samples. We
screened a small sample size of 15 tumor lysates andimmunoblotted for ZNF217 and ERα. Densitometry in-
dicated a high correlation for ZNF217 and ERα protein
expression (r2 = 0.93) in the tumor samples (Figure 6E).
ZNF217 expression is prognostic of reduced survival in
patients with ER+ and Luminal A breast tumors
To further explore the effect of ZNF217 expression on
patient survival we interrogated the Kaplan Meier-plotter,
an online survival analysis tool, for overall survival in
breast cancer patients to rapidly assess the effect of 22,277
genes on breast cancer prognosis using microarray data of
1,809 patients [38]. We compared all ER+ patients (all in-
trinsic subtypes with any therapy) and found that high
ZNF217 expression was associated with lower overall sur-
vival (p = 0.03, Figure 7A). To determine whether ZNF217
was simply identifying the poorer prognosis Luminal B tu-
mors from within the Luminal cohort, we asked whether
ZNF217 expression had prognostic value in the ER+ Lu-
minal A tumors or the ER+ Luminal B tumors (with any
Figure 7 ZNF217 expression is prognostic of reduced survival in patients with ER+ and Luminal A breast tumors. ZNF217 gene expression
was analyzed using the Kaplan Meier-Plotter, an online survival analysis tool to analyze gene expression with breast cancer prognosis using microarray
data from 1,809 patients [38]. High ZNF217 expression affects Overall Survival in Luminal A but not Luminal B ER+ breast cancer patients (any systemic
anti-hormonal therapy treatment and/or chemotherapy). The prognostic value of high ZNF217 expression (median cutoff) was compared to the
patient cohort with low ZNF217 expression in (A) All ER+ patients (n = 823), p = 0.03. (B) Luminal A (n = 504), p = 0.035 (C) Luminal B (n = 319), p = 0.96.
(D) High ZNF217 correlates with worse survival in ER+ patients treated with any endocrine therapy (but not chemotherapy). The prognostic
value of high ZNF217 (n = 78) expression (upper quartile) was compared to the patient cohort with low ZNF217 expression (n = 236), p = 0.01.
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high ZNF217 expression is associated with lower overall
survival in the Luminal A tumors (p = 0.035). Interest-
ingly, the data for Luminal B tumors expressing high
ZNF217 did not reach statistical significance (Figure 7C).
This finding suggests that ZNF217 provides additional
prognostic information, beyond ERα status and Luminal
subtype.
ZNF217 expression is prognostic of reduced survival after
hormone treatment of ER+ breast cancer patients
The high overlap between differentially regulated genes
co-bound by ZNF217 and ERα and the poor prognosis of
patients with breast tumors that overexpress ZNF217 sug-
gested that ZNF217 may have a regulatory role in expres-
sion changes that occur in tamoxifen-resistant breast
tumors. To determine if high ZNF217 expression corre-
lates with reduced overall survival in the cohort of ER+ pa-
tients that received anti-hormone therapy only (without
the confounding effects of chemotherapy), we explored
n = 78 patients with high versus n = 236 low ZNF217 ex-
pression in the Kaplan Meier-plotter (Figure 7D). Patientswith high ZNF217 expression (upper quartile) demon-
strated worse outcome p = 0.05.
Discussion
In this work we have mapped the chromatin landscape
surrounding ZNF217 DNA binding sites and found sig-
nificant overlap between ZNF217 binding and transcrip-
tion factors associated with the ERα regulatory network.
ZNF217 predominantly occupies distal regulatory re-
gions marked by the active histone marks H3K27ac and
H3K4me1 and, depending on the chromosomal context,
may participate either in the repression or the activation
of gene expression. A similar mode of action for ER-
mediated gene regulation has been proposed where ERα
associates with auxiliary TFs and co-regulators in a spe-
cific chromosomal context to control gene expression,
although it is not well understood what specifies the
context-dependent activity of this regulation. In support
of a transcriptional role for ZNF217 in aberrant ERα sig-
naling, we identified a ZNF217-ERα gene signature with
ontological classification that aligns with multiple breast
cancer studies (Figure 5). Data-mining of expression data
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expression with poor prognosis across multiple intrinsic
subtypes and reduced response to hormone therapy
(Figure 7).
The function of ER binding at chromatin regions and
transcriptional regulation is strongly influenced by GATA3
and FOXA1 [39-42]. GATA3 appears to function as a crit-
ical regulator of transcription factor binding, chromatin
structure, and long-range genomic communication [43].
FOXA1 is known as a pioneer factor, a special class of
transcription factors that bind to condensed chromatin
and facilitate the binding of additional transcription fac-
tors [22]. An elegant study by Ross-Innes et al., mapped
the genome-wide ER-binding events by ChIP-seq in pri-
mary breast cancers from patients with different clinical
outcomes [44]. They found distinct ER binding co-
factor combinations linked with the different clinical
outcomes, and that FOXA1 appears to mediate the dif-
ferential ER-binding profiles found in clinical subtypes.
However it is still unknown what dictates the differen-
tial FOXA1 and subsequent ERα binding. At the gen-
ome level approximately a quarter of all ERα -binding
events are co-occupied by GATA3 and FOXA1 [43].
Similarly, we found an enrichment of GATA3 and FOXA1
factors at ZNF217-bound regions (Figure 3A). Our results
suggest ZNF217-bound regions may be co-occupied with
ERα and FOXA1 at multiple ERα gene targets, including
TFF1, ERBB3, SLC22A5, and LRIG1 (Additional file 3:
Figure S1B and Additional file 11: Figure S6). Knock-
down of ZNF217 followed by expression profiling iden-
tified 3,402 differentially affected genes suggesting a
functional regulatory role linked to multiple signaling
pathways associated with breast cancer (Figure 5 and
Additional file 12: Table S6). Future work will determine
whether ZNF217 binding to ERα cis-regulatory se-
quences contributes an additional level of regulation to
ERα-binding potential and ERα-signaling. Multiple regula-
tory scenarios are possible and include ZNF217 promo-
tion of chromatin accessibility through recruitment of
chromatin remodeling factors or regulation of three-
dimensional chromatin to spatially connect distal enhan-
cer regions with proximal promoters. It will be interesting
to unravel the potential regulatory role for ZNF217 signal-
ing and whether ZNF217 co-operates or competes with
ERα regulatory factors such as GATA3 and FOXA1.
Interestingly, ZNF217 and GATA3-FOXA1 are associ-
ated with opposite tumor phenotypes. Well-differentiated
tumors are generally less advanced and support a better
prognosis than poorly differentiated tumors that are more
aggressive and correlate with poorer prognosis. The regu-
lation of cell differentiation during normal development
involves transcription factors that are increasingly associ-
ated with tumorigenesis upon their aberrant re-activation
and expression. Recently, GATA3 has been shown to playan important role at multiple stages of mammary gland
development, including the formation of terminal end
buds in luminal cell differentiation [45]. GATA3 is a strong
predictor of tumor grade, ER status, well-differentiated tu-
mors, and a marker of good prognosis. Loss of GATA3 co-
incides with loss of differentiation and tumor metastasis
[45]. Similar to GATA3, FOXA1 plays a role in postnatal
development of the mammary gland, perhaps due to its re-
quirement for ERα chromatin binding and activity [46,47].
Both GATA3 and FOXA1 expression are part of the Lu-
minal A molecular subtype gene signature [48], associated
with well-differentiated tumors and better prognosis. Tu-
mors negative for GATA3 and FOXA1 expression associate
with poorly differentiated tumors and malignant progres-
sion [45,46].
In contrast to GATA3 and FOXA1, the ZNF217 gene
is amplified at 20q13 in ~20% of breast tumors and is
associated with aggressive breast disease [1,3,49]. Our
recent studies show the overexpression of ZNF217 pro-
motes cell plasticity particularly in the maintenance of
the de-differentiated stem-like cell state, and accelerates
tumor progression and metastasis [3]. Our findings that
ZNF217 interacts physically with ERα and that ZNF217
occupies chromatin regions also occupied by ERα,
GATA3, and FOXA1 will require further investigation to
understand whether ZNF217 is one of the multiple fac-
tors that contribute to ERα chromatin binding and ERα
gene regulation.
Data-mining of microarray expression data from pri-
mary breast tumors and the corresponding clinical data
showed high ZNF217 expression correlates with shorter
overall survival and relapse-free survival [3]. Our current
studies demonstrate a high correlation between ZNF217
and ERα expression in breast cancer cell lines and breast
tumor tissue, yet the precise role of ZNF217 in ER+
breast cancer is not fully understood. Studies conducted
over 10 years ago using microarray technology revealed
tumor heterogeneity at the gene expression level and led
to the identification of breast cancer subtypes [48,50,51].
The ER+ subtypes, referred to as Luminal A and Lu-
minal B, have different gene-expression profiles, progno-
sis and treatment responses [48,50-52]. When compared
to the Luminal A subtype, Luminal B tumors often have
lower expression levels of ERα or ER-regulated genes,
higher tumor grade, activation of growth factor receptor
signaling pathways and reduced sensitivity to chemo-
therapy than Luminal A tumors [53]. Despite the divi-
sions between Luminal A and B subtypes, the heterogeneity
found in ER+/− and luminal tumors suggests further stratifi-
cation is necessary to enable more accurate prognosis and
treatment plan for individual patients [53]. Our findings
suggest that ZNF217 overexpression in ER+, Luminal A, or
other subtypes of breast cancer will identify a subset of pa-
tients with worse prognosis who will benefit from more
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the ZNF217-ER gene signature aligning with multiple
breast cancer studies further supports a transcriptional
role for ZNF217 in aberrant ERα signaling (Figure 5).
Future investigations will explore the connection be-
tween ZNF217 expression levels in breast tumors with
clinical outcome and, importantly, whether ZNF217
plays a transcriptional role in aberrant ERα signaling,
contributing to breast cancer and therapy resistance.
Conclusions
In this genome-wide study we show the distribution
of ZNF217 binding events coincide with GATA3,
FOXA1, and ERα binding. Motif analysis and co-
immunoprecipitation assays implicate ZNF217 in a
co-regulatory role with ERα at co-bound regions. The
understanding of the chromatin landscape at ZNF217-
bound regions is beginning to provide insight into a
relationship between ZNF217 and ERα to modulate en-
hancer accessibility, ERα-binding potential, and gene regu-
lation. Additional studies are underway to explore the
requirement of ZNF217 in ERα gene regulation at co-
bound sites prior to estrogen stimulation. Our findings
contribute to the genome-wide potential of ZNF217 in the
hierarchy of ERα-mediated regulation by multiple tran-
scription factors and provide a possible mechanism by




The MCF7 breast cancer cell line was obtained from
American Type Culture Collection and cultured in
Dulbecco’s Modified Eagle’s Medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine and
1% penicillin/streptomycin.
Primary human tissue specimens
Frozen human breast tumor specimens were provided
by the UCD Cancer Center Specimen Repository and
the NCI Cooperative Human Tissue Network. All sam-
ples were de-identified, and the study was approved by
the Institutional Review Board of the UCD School of
Medicine. Frozen tissues were homogenized in ice-cold
T-PER Tissue Protein Extraction Reagent (Pierce) with
protease and phosphatase inhibitors, and then centri-
fuged to remove insoluble debris.
siRNA-mediated silencing
MCF7 cells were reverse-transfected at a density of 5 × 105
per well in 6-well culture plates. Transfection was per-
formed using 100 nM siRNA targeting ZNF217 (OnTar-
get plus SMARTpool, Dharmacon, cat # L-004987-01)
or non-targeting pool (OnTarget plus non-targetingpool, Dharmacon, cat # D-001810-10) using RNAiMax
(Invitrogen) per the manufacturer’s instructions. RNA
was collected at 48 h post-transfection.
RNA isolation and real-time qPCR
RNA samples for RNA-seq or cDNA synthesis were
purified using a commercial kit (Qiagen; RNAeasy Kit).
RNA (2.5ug) was converted to cDNA using the High
Capacity cDNA Reverse Transcription Synthesis Kit
(Applied Biosystems). Analyses were performed using
TaqMan Gene Expression Assays (Applied Biosystems;
listed in Additional file 15: Supplemental Methods) on
the BioRad CFX 9600 thermocycler.
Co-immunoprecipitation assays
A total of 1x107 MCF7 cells were grown in complete
medium and harvested after washing with PBS. The cel-
lular nuclear extracts were isolated with a Nuclear Ex-
traction Kit and provided protocol (Affymetrix cat
#AY2002). Immunoprecipitation was performed with 5
ug of antibody or negative IgG control from rabbit on
pre-cleared nuclear extracts. After overnight incubation,
protein G agarose beads were added for 2 h. The beads
were washed in co-IP buffer (20 mM Tris ph 7.5,150 mM
NaCL, 1% NP40,10% glycerol,1 mM MgCl2), boiled
5 min at 95°C and run on an 8% acrylamide gel. Anti-
bodies: ZNF217 column-purified rabbit polyclonal [4],
ERα (Santa Cruz Biotechnology; cat #scbt-543), CtBP2
(BD Transduction cat #612044), and IgG from rabbit
serum (Sigma cat #15006).
ChIP-seq assays
Chromatin immunoprecipitation (ChIP) was performed
following the method previously described [54]. Briefly,
crosslinked chromatin was collected from MCF7 cells
asynchronously grown in full media at 80% confluence.
ZNF217 antibody (previously described [4]), H3K4me3,
H3K9me3, or H3K27me3 antibodies were incubated
with sonicated chromatin overnight. Libraries were con-
structed and analyzed using an Illumina Hiseq2000.
ChIP-seq experiments were performed in duplicate using
MCF7 cells grown on different days using independently
performed ChIP assays. Replicate input chromatin sam-
ples were also included as a control. Additional ChIP as-
says were performed for ERα (Santa Cruz Biotechnology;
cat #scbt8002) and FOXA1 (Abcam #23738). ChIP-
qPCR was performed using iQ SYBR Green Supermix
(BioRad). Primers used to validate TF binding are listed
in Additional file 15: Supplementary Methods.
ChIP-seq data processing
All ChIP-seq datasets were processed by first aligning
sequence reads to the hg19 genome using Bowtie2 [55].
We obtained the raw read data files for the ChIP-seq
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GATA3 from asynchronously grown MCF7 cells from
previously published studies [41,56,57]. H3K27ac and
H3K4me1 ChIP-seq data generated in asynchronously
grown MCF7 cells was obtained from [57]. All transcrip-
tion factor and histone modification peaks were called
using Sole-Search software using sequenced MCF7 input
as a control [12,58]. For ZNF217, we used the ENCODE
overlap rules to evaluate the reproducibility of the two
biological replicates for each factor or histone modifica-
tion and cell-type combination [13]. For this, we first
truncated the peak lists of the two replicates for a given
factor/cell-type combination so that both the A and B
replicate peak list were the same length. Then, we over-
lapped the top 40% of the replicate A peak list with the
entire replicate B peak list (and vice versa). ENCODE
standards state that approximately 80% of the top 40%
set should be contained in the larger set. After determin-
ing that replicate datasets met this standard, we merged
the two replicates and called peaks on the merged
dataset.
TF Co-association
Co-occurance analysis to study the overlap of ZNF217
with other transcription factor binding sites was per-
formed using the Aggregation and Correlation Tool (ACT
Tool) [59]. The signal files corresponding all MCF7
transcription factor binding regions were obtained from
the ENCODE project (https://genome.ucsc.edu/ENCODE/
downloads.html). Using these signal tracks and peak lists
for transcription factor we used the ACT tool to per-
form the signal aggregation over each peak list. The
resulting matrix was clustered using Cluster3.0 [60]
using a Pearson Correlation distance metric and was vi-
sualized in R.
RNA-seq
RNA samples from triplicate biological replicates of
MCF7 cells treated with scrambled siRNA or siZNF217
were extracted using the RNAeasy Kit (Qiagen). 2 ug of
RNA samples were processed with the TruSeq RNA
Sample Prep Kit (Illumina) to make RNA libraries fol-
lowing the Low-Throughput protocol. Libraries were
prepared and sequenced using the HiSeq2500 platform
at the UC Davis DNA Technologies Core Facility (http://
dnatech.genomecenter.ucdavis.edu).
RNA-seq data processing
RNA-seq data was processed using TopHat and Cufflinks
[61,62] as described [63].
Additional supporting data
All data are publicly available via the UCSC Genome
ENCODE Browser and/or has been submitted to theGene Expression Omnibus. The NCBI accession number
for the RNAseq data is GSE58326. http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE58326. The NCBI ac-
cession number for the ZNF217 ChIPseq data is
GSM935563.
Additional files
Additional file 1: Table S1. ZNF217 binding sites from merged
ChIP-seq datasets. ZNF217 peaks were called using Sole-Search peak
calling software [12,58] on replicate datasets (see Methods for details).
A total of 18,965 ZNF217 binding events are listed.
Additional file 2: Table S2. ZNF217-associated genes (6,965) from
ChIP-seq binding sites.
Additional file 3: Figure S1. ChIP-qPCR confirming TF binding sites
identified by ChIP-seq. (A) Panel of ZNF217-bound distal sites confirmed
by ChIP-qPCR. (B) Relative TF ChIP enrichment at the ERα target genes
ERBB3, TFF1, and LRIG1. ChIP assays were performed on two independent
biological replicates using the following antibodies ZNF217, ERα and
FOXA1. IgG was used as a control. Relative DNA enrichment was
calculated relative to DNA input and using the non-target ZNF10 locus
as a negative control.
Additional file 4: Figure S2. Location Analysis of ZNF217 epigenomic
clusters. Location analysis of the cluster I region and cluster II region from
Figure 1B. The fraction of the ZNF217 binding sites found in cluster I
(top chart) or cluster II (below chart) relative to Refseq genes is shown.
Additional file 5: Table S3. GREAT annotation of top 5 k ZNF217-
associated genes. Table showing GO Biological Process category from
gene analysis using the GREAT web tool.
Additional file 6: Figure S3. de novo ZNF217 motif. Identification of de
novo motif for ZNF217 binding sites in MCF7 cells. HOMER de novo motif
analysis using the central most 100 base pairs of all 18,965 ChIP-seq
binding regions reveal the indicated motif (shown in both forward and
reverse complement).
Additional file 7: Figure S4. Venn diagram for ZNF217 and ER binding
overlap. Overlap analysis of ZNF217 and ERα ChIP-seq binding sites in
MCF7 cells. The Venn diagram illustrates the total number of genomic
regions shared between these two factors (overlapping by at least 1 base
pair). The total number of identified sites is indicated below each factor’s
name.
Additional file 8: Table S4. 4-way Venn Diagram Gene Overlap for
multiple TF binding. sites. Excel file contains multiple worksheets listing
the ZNF217, ERα, FOXA1 and GATA3-associated genes and co-bound
genes for TF combinations.
Additional file 9: Figure S5. Validation of ZNF217 knockdown for
RNA-sequencing. MCF7 cells were reverse transfected with scrambled
or ZNF217 siRNA for 48 h. Cells were collected from each well and split
into two samples for RNA isolation and protein lysate. (A) Protein lysates
from triplicate samples were immunoblotted for ZNF217 or actin as a
loading control. Chemoluminescence was analyzed on an Alpha-Innotech
Imaging documentation system. (B) RNA samples were converted to
cDNA and quantitative RT-PCR performed using ABI expression assay
Taqman probes for ZNF217 and GAPDH. Each sample was assayed in
triplicate and the cT values were normalized to GAPDH. Average relative
transcript level was graphed using BioRad CFX software. Columns:
transcript levels, error bars: standard error of the mean.
Additional file 10: Table S5. Differentially expressed genes from
RNA-seq. List of the 3,402 differentially expressed genes; 1,615 genes
were up-regulated and 1,787 were down-regulated genes in the ZNF217
knockdown sample, as compared to the control siRNA-treated sample
(at 1.25 -fold change cutoff and criteria representing statistical
significance, false discovery rate (FDR) < 0.0001.
Additional file 11: Figure S6. Integrated Genome Browser snapshots
of 4 genes bound by ZNF217, ERα, FOXA1 and GATA3. Co-bound regions
are shown for LRIG1, AXIN1, SLC22A5, and IGFBP4.
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http://www.biomedcentral.com/1471-2164/15/520Additional file 12: Table S6. MSigDB cancer studies for 1,230 and 854
gene lists. Worksheets with complete list of all MSigDB cancer studies
resulting from GREAT analysis for ZNF217-bound genes versus ZNF217-ER
co-bound genes.
Additional file 13: Figure S7. ERα co-immunoprecipitation with
ZNF217 and CtBP2. Co-immunoprecipitation of endogenous ZNF217, ERα
and CtBP2 from MCF7 nuclear extracts. Immunoprecipitation experiments
with ERα antibody to co-IP ZNF217 were blotted with corresponding
antibodies. CtBP2 is a ZNF217-binding partner. Input from nuclear extracts is
shown in the two left lanes.
Additional file 14: Figure S8. Overall Survival in ER- and Basal breast
cancer patient cohorts. A) Overall survival of basal subtype patients
(n = 30) based on ZNF217 expression from primary tumors for low
(n = 19) versus high (n = 11) ZNF217 expression (P = 0.01; Logrank).
B). Overall survival in ER- patients based on ZNF217 expression for low
ZNF217 (n = 24) versus high ZNF217 (n = 17) (P = 0.005; Logrank). Data
was sorted first by ZNF217 expression using the median cutoff. Then the
data was sorted to identify the ZNF217 high patients and the ZNF217
low patients who were ER- or basal patients. Expression Data from Chin
et al., [36].
Additional file 15: Supplementary Methods. Primers used to validate
TF binding sites and Taqman Assays for RNA-seq confirmations.Abbreviations
ZNF217: zinc finger protein #217; ER/ERα: Estrogen receptor alpha;
GATA3: GATA binding protein 3; FOXA1: forkhead box A1; H3K27ac:
Histone H3 acetylated on Lysine 27; H3K4me1: Histone H3 monomethylated
on Lysine 4; LSD1: Histone demethylase; HDAC: Histone deacetylase; Jarid1b/
Plu-1: Lysine (K)-specific demethylase; G9a: Euchromatic histone-lysine
N-methyltransferase; EZH2: Enhancer of zeste homolog 2; siRNA: Small
interfering RNA; ChIP-qPCR: Chromatin immunoprecipiation-quantitative
PCR; MSigDB: Molecular signature database; GREAT: Genomic Regions of
Enrichment Annotation Tool; TFs: Transcription factors.
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